Sarepta Therape Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sarepta Therape (US): 4 reconciled FDA prescription therapies, $708.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$708.0M
2024 Medicare Part D Spend$45.1M
2024 Medicaid Spend$662.9M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.